Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians.
It is a $12.6B healthcare company. Revenue grew 17.6% over the last year, and it keeps 11¢ of every dollar of sales as profit. It trades at 78.3× earnings — in the cheapest third of its own history.
- Website
- penumbrainc.com
- Location
- Alameda, CA
- Employees
- 4 700
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong health and quality; Valuation and Moat lag behind.
Valuation37
- P/E vs own history24th pct · 20/25
- FCF yield1.7% · 5/25
- P/S8.4x · 12/25
- EV/EBITDA66.0x · 0/25
Growth65
- Revenue CAGR17.1% · 20/25
- Net income CAGR140.8% · 25/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growth16.5% · 20/25
Profitability64
- ROIC20.1% · 20/25
- ROE11.1% · 12/25
- Net margin10.7% · 20/25
- Operating margin12.4% · 12/25
Health75
- Altman Z18.49 · 25/25
- Current ratio5.75 · 25/25
- Interest coverageno interest expense · 25/25
- Net cash / debtn/a · 0/25
Quality90
- Piotroski F8/9 · 25/25
- Beneish M-2.46 · 20/25
- FCF conversion134% · 25/25
- Margin stabilityσ 5.7% · 20/25
Moat40
- ROIC >12% years1/10 yrs · 0/25
- Median gross margin64.7% · 25/25
- FCF-positive years6/10 yrs · 10/25
- Worst-year net marginworst -2.8% · 5/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2025FinancialBest year on record$178M net income
- FY2023FinancialRevenue crossed $1B$1.06B for the year
- FY2016FinancialFirst recorded profitable year$14.8M net income
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (67.8%)
- Revenue growing 17.6% year over year
- High returns on invested capital (ROIC 20.1%)
- Piotroski F-Score 8/9 — fundamentally strong checklist
- Altman Z-Score 18.49 — low bankruptcy-risk zone
Watch-outs
- Loss-making in 2 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+17.6% YoY
- Profitable — makes more than it spends$161M TTM
- Profit growing — earnings are higher than last year+1168.1% YoY
- Generates cash — cash left after running and investing$216M TTM
- Debt under control — could handle its obligationscurrent ratio 5.75
- Established company — not a micro-cap — lower blow-up risk$12.6B market cap
- Not printing shares — share count not ballooning — you keep your slice+9.9% shares over ~5y
- Proven track record — years of profitability behind it8/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 18.5 — safe
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 78.3
Peer comparisonPenumbra, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| PEN this company | $12.6B | 78.3 | +17.6% | 10.7% | Strong |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: PEN vs LLY · PEN vs JNJ · PEN vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/PEN
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of PEN on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $319.40 · market cap $12.6B.